South Korea-based drug development company DAAN Biotherapeutics has entered an exclusive licensing agreement with gene and cell therapy company GC Cell.
The agreement allows GC Cell to use DAAN Biotherapeutics’ tumour antigen-specific antibody sequence for developing CAR-T and CAR-NK therapies.
The collaboration will focus on an antibody that will advance the treatments for solid tumours, including lung and colorectal cancers.
The antibody targets a tumour antigen that is overexpressed in several solid cancers, which is crucial for developing next-generation cancer therapies.
DAAN Biotherapeutics’ antibody offers enhanced specificity, which could reduce side effects and improve therapeutic outcomes compared to existing treatments.
The collaboration combines GC Cell’s advanced CAR cell-therapy technology with DAAN Biotherapeutics’ antibody expertise.
The synergy is expected to significantly enhance the effectiveness of CAR cell therapies.
The agreement includes an upfront payment, milestone payments, and royalties based on future sales, although specific financial details remain confidential.
DAAN Biotherapeutics CEO Byoung-Chul Cho said: “We will continue to innovate our technologies to develop cancer treatments that will change the lives of patients.”
Earlier in the year, DAAN Biotherapeutics signed a similar agreement with LigaChem Biosciences to advance Antibody-Drug Conjugates (ADC) for solid tumour patients.
Through a strategic partnership with OmniAb, DAAN Biotherapeutics has established a pipeline for developing antibodies targeting overexpressed tumour antigens in solid cancers.
